332 ENCINITAS BOULEVARD, ENCINITAS, CA
Market cap: $7.9M (12/18/2025)
Price: $2.16
Reports Third Quarter 2025 Results; Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases
Investor Presentation
Reports Second Quarter 2025 Results; Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases
News
Partner on KIO-301 for the Treatment of Retinal Diseases in Asia
Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027
Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-term Investments Expected to Fund Operations into 2027
News, Material Contracts
Q3
Q2
Q1
FY 2024
FY 2023
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Notice of Exempt Offering of Securities
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership